Search

Arcus Biosciences Inc

Ouvert

SecteurSoins de santé

24.99 1.09

Résumé

Variation du prix de l'action

24h

Actuel

Min

24.37

Max

25.25

Chiffres clés

By Trading Economics

Revenu

37M

-91M

Ventes

24M

41M

BPA

-0.72

Marge bénéficiaire

-221.951

Employés

601

EBITDA

38M

-85M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+54.59% upside

Dividendes

By Acuity

Prochains Résultats

26 oct. 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-210M

3.3B

Ouverture précédente

23.9

Clôture précédente

24.99

Sentiment de l'Actualité

By Acuity

50%

50%

95 / 339 Classement par Healthcare

Arcus Biosciences Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

25 sept. 2026, 23:50 UTC

Arcus Biosciences Inc is trading lower in after-hours, reaching its lowest point of the day and remaining well below its 20-day moving average.

24 sept. 2026, 20:01 UTC

Arcus Biosciences Inc shares fell sharply, continuing a downward trend from Wednesday's close and trading well below its 20-day moving average.

23 sept. 2026, 20:07 UTC

Correlated Moves

Arcus Biosciences Inc shares fell amid a broader market downturn and rising U.S. Treasury yields, despite earlier reaching a session high.

22 sept. 2026, 20:06 UTC

Arcus Biosciences Inc is advancing amid a strong biotechnology sector, gaining ground since Monday's close but remains below its 20-day moving average.

21 sept. 2026, 19:16 UTC

Arcus Biosciences Inc is trading higher since Friday's close, despite being below its 20-day moving average and near the lower end of its one-month range.

18 sept. 2026, 20:13 UTC

Arcus Biosciences Inc is advancing in after-market trading following Friday's close, despite being positioned below its 20-day moving average.

17 sept. 2026, 19:36 UTC

Correlated Moves

Arcus Biosciences is advancing, building on prior momentum, amid a broader biotech sector uptick driven by positive Phase 3 results from Moderna's cancer vaccine trial.

16 sept. 2026, 23:06 UTC

Arcus Biosciences Inc is trading slightly higher in after-market hours, recovering from an earlier dip but remains below its 20-day moving average.

15 sept. 2026, 19:36 UTC

Correlated Moves

RCUS lower today, tracking declines in SPDR S&P Biotech ETF.

14 sept. 2026, 20:21 UTC

Arcus Biosciences Inc shares are lower in after-market hours, marking seven consecutive sessions of declines. No specific news was identified for the price movement.

11 sept. 2026, 21:21 UTC

Arcus Biosciences Inc shares are lower in after-market trading, continuing a recent trend. No specific company news was identified to explain the decline.

10 sept. 2026, 20:01 UTC

Arcus Biosciences Inc shares are sharply lower today, breaking a recent trend of higher closes. Unusually high trading volume may be influencing the decline.

9 sept. 2026, 20:07 UTC

News

Shares of Arcus Biosciences are lower today, despite anticipation of a significant data update in October following a recent presentation at Citigroup's summit.

8 sept. 2026, 20:07 UTC

Arcus Biosciences Inc shares are lower today, continuing a decline since Friday's close. The stock is trading near the lower end of its one-month range.

2 sept. 2026, 20:08 UTC

Correlated Moves

Arcus Biosciences Inc. shares are higher today, supported by gains in the biotechnology sector and trends in related ETFs. The stock has stabilized after fluctuations.

28 août 2026, 20:02 UTC

Arcus Biosciences shares are lower today, breaking a trend of higher closes. Rising U.S. Treasury yields may be impacting investor sentiment in biotechnology.

26 août 2026, 20:08 UTC

Arcus Biosciences Inc shares are lower during Wednesday's session amid mixed market performance and inflation data, with no specific company news identified for the decline.

20 août 2026, 19:36 UTC

Correlated Moves

Arcus Biosciences shares are lower, reflecting a broader decline in the biotechnology sector amid first-quarter results indicating a notable drop in price.

19 août 2026, 19:46 UTC

Correlated Moves

Arcus Biosciences Inc is trading higher, supported by a positive trend in the biotechnology sector. The stock remains above its 20-day moving average.

18 août 2026, 20:06 UTC

Arcus Biosciences Inc. shares are trading roughly flat amid no specific news. The stock remains above its 20-day moving average.

17 août 2026, 19:16 UTC

News

Arcus Biosciences Inc is rising as biotechnology sector momentum continues. The company reported second-quarter revenue of $41 million and a net loss of $91 million.

14 août 2026, 19:46 UTC

Arcus Biosciences Inc is higher today, continuing a positive trend since Thursday's close. The stock remains above its 20-day moving average.

11 août 2026, 19:56 UTC

News

HC Wainwright raised Arcus Biosciences' Q3 2026 EPS estimate to -$1.00 and maintained a "Buy" rating with a price target of $45.00.

10 août 2026, 21:02 UTC

Arcus Biosciences Inc shares are higher in after-market trading, continuing a strong upward trend since Monday's close, well above the 20-day moving average.

7 août 2026, 19:36 UTC

Arcus Biosciences Inc. shares are higher today, trading within a typical range amid investor uncertainty over future monetary policy following a weak jobs report.

6 août 2026, 20:03 UTC

News

Arcus Biosciences shares are higher as Wells Fargo raises its price target to $23.00 and Wedbush increases its target to $43. Trading volume is notably high.

5 août 2026, 20:21 UTC

News

Arcus Biosciences reported a net loss of $91 million but exceeded revenue expectations with $41 million. Shares are higher in after-market trading.

4 août 2026, 21:02 UTC

Arcus Biosciences Inc shares are higher in after-market trading, reflecting positive market sentiment amid easing inflation concerns from U.S.-Iran negotiations.

3 août 2026, 19:36 UTC

Arcus Biosciences shares are lower today, reflecting broader market dynamics and geopolitical developments impacting investor sentiment. Earlier, shares peaked before declining.

31 juil. 2026, 23:16 UTC

Arcus Biosciences Inc. shares are lower in after-market hours, continuing a trend of declining prices and remaining below the 20-day moving average.

Comparaison

Variation de prix

Arcus Biosciences Inc prévision

Objectif de Prix

By TipRanks

54.59% hausse

Prévisions sur 12 Mois

Moyen 38.6 USD  54.59%

Haut 47 USD

Bas 23 USD

Basé sur 11 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

11 ratings

8

Achat

3

Maintien

0

Vente

Sentiment

By Acuity

95 / 339Classement par Soins de santé

Sentiment de l'Actualité

Neutral

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Arcus Biosciences Inc

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.